Vanessa S. Rodrik-Outmezguine
Showed that tumours reactivate AKT after mTOR kinase inhibition, and that the third-generation inhibitor RapaLink-1 overcomes mTOR resistance mutations
Associate VP, Clinical Biomarker Development, Loxo Oncology at Lilly · Precision Medicine (Associate Director, then Director), Novartis Oncology (2017–2021) · Research Fellow to Senior Scientist, Rosen Lab, MSKCC (2006–2017) · PhD in Molecular Biology, CUNY Graduate Center (2006)
Portrait: Clinical Genomic Biomarkers Summit 2025, speaker page
Led ROD2011 (Cancer Discovery): mTOR-kinase inhibitors trigger a biphasic AKT rebound via feedback release of upstream RTK signaling. Led follow-up ROD2016 (Nature, with Shokat's chemistry group): RapaLink-1, a bivalent third-gen inhibitor bridging mTOR's two drug pockets, overcomes resistance mutations.
After eleven years in Neal Rosen's lab at Memorial Sloan Kettering she moved from academic pharmacology into translational science: first precision medicine at Novartis Oncology, then clinical biomarker development at Lilly (Loxo Oncology), where she shapes biomarker strategy for precision-oncology trials.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2011 | M | mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling ROD2011 mTOR-kinase inhibitors trigger feedback-dependent biphasic AKT rebound. |
| 2016 | M | Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor ROD2016 RapaLink-1 overcomes resistance mutations that defeat first/second-gen mTOR inhibitors. |
Co-authors in the Atlas 4
People with a profile here who share at least one study with Vanessa S. Rodrik-Outmezguine.
ShowHide
- Neal Rosen 2 shared studies Showed that blocking mTORC1 releases a feedback brake on receptor tyrosine kinases and AKT, explaining how tumours escape mTOR and PI3K inhibitors and shaping how these drugs are combined in the clinic
- José Baselga Breast cancer oncologist who led the BOLERO-2 trial showing that the mTOR inhibitor everolimus added to hormone therapy lengthens progression-free survival
- Kevan M. Shokat Co-developed the ATP-competitive 'TORKinib' mTOR inhibitors that block both mTORC1 and mTORC2, and later, with Neal Rosen's lab at Memorial Sloan Kettering, RapaLink-1, a third-generation inhibitor that overcomes mTOR resistance mutations
- Sabina Cosulich Cancer drug discovery scientist at AstraZeneca whose work spans PI3K and mTOR pathway inhibitors, PARP1 inhibitors and phosphoinositide lipid signalling
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.